Proactiveinvestors RSS feed en Sun, 25 Feb 2018 12:36:46 +1100 Genera CMS (Proactiveinvestors) (Proactiveinvestors) <![CDATA[RNS press release - Scancell to present at the Calculus Investor Forum ]]> Fri, 16 Feb 2018 22:30:01 +1100 <![CDATA[RNS press release - Hardman Res. - Validating multiple opportunities ]]> Thu, 15 Feb 2018 18:15:01 +1100 <![CDATA[RNS press release - Collaboration agreement with ISA Pharmaceuticals ]]> Thu, 15 Feb 2018 18:00:04 +1100 <![CDATA[RNS press release - Publication highlights potential of SCIB1 therapy ]]> Mon, 12 Feb 2018 18:00:03 +1100 <![CDATA[RNS press release - European patent application allowed for grant ]]> Fri, 09 Feb 2018 18:00:03 +1100 <![CDATA[RNS press release - Scancell member of team shortlisted for CRUK award ]]> Thu, 08 Feb 2018 18:00:06 +1100 <![CDATA[RNS press release - Director/PDMR Shareholding ]]> Thu, 01 Feb 2018 18:00:13 +1100 <![CDATA[RNS press release - Half-year Report ]]> Tue, 30 Jan 2018 18:00:03 +1100 <![CDATA[RNS press release - Scancell to collaborate with BioNTech ]]> Tue, 09 Jan 2018 18:00:02 +1100 <![CDATA[RNS press release - Scancell and CRUK to advance cancer immunotherapy ]]> Thu, 14 Dec 2017 18:00:03 +1100 <![CDATA[RNS press release - Result of AGM ]]> Wed, 11 Oct 2017 19:44:37 +1100 <![CDATA[RNS press release - Directorate Change ]]> Tue, 10 Oct 2017 17:00:04 +1100 <![CDATA[RNS press release - Notice of AGM ]]> Thu, 14 Sep 2017 16:00:07 +1000 <![CDATA[RNS press release - Final Results ]]> Wed, 13 Sep 2017 16:00:04 +1000 <![CDATA[RNS press release - Presents Moditope Data at Immunotherapy Conference ]]> Mon, 11 Sep 2017 16:00:06 +1000 <![CDATA[RNS press release - Oncimmune and Scancell Present Autoantibodies Data ]]> Tue, 29 Aug 2017 16:00:08 +1000 <![CDATA[RNS press release - Continued Progress on SCIB1 ]]> Tue, 11 Jul 2017 16:00:02 +1000 <![CDATA[RNS press release - DNA ImmunoBody Patent Granted in Europe ]]> Mon, 26 Jun 2017 16:00:06 +1000 <![CDATA[RNS press release - Holding(s) in Company ]]> Mon, 22 May 2017 21:59:15 +1000 <![CDATA[RNS press release - Holding(s) in Company ]]> Fri, 19 May 2017 23:47:19 +1000 <![CDATA[RNS press release - Holding(s) in Company ]]> Fri, 19 May 2017 16:00:07 +1000 <![CDATA[RNS press release - Results of Placing ]]> Thu, 11 May 2017 21:09:44 +1000 <![CDATA[RNS press release - Proposed Placing to Raise up to £5.0 million ]]> Thu, 11 May 2017 16:00:14 +1000 <![CDATA[RNS press release - Change of Registered Office ]]> Thu, 13 Apr 2017 21:39:40 +1000 <![CDATA[RNS press release - Immuno-Oncology Summit Europe 2017 ]]> Mon, 20 Mar 2017 18:00:10 +1100 <![CDATA[RNS press release - Hardman Research: SCIB development update ]]> Mon, 13 Mar 2017 18:15:02 +1100 <![CDATA[RNS press release - Holding(s) in Company ]]> Wed, 01 Mar 2017 18:00:23 +1100 <![CDATA[RNS press release - Results of AGM ]]> Wed, 19 Oct 2016 03:42:47 +1100 <![CDATA[RNS press release - Preparing SCIB2 for clinical study in lung cancer ]]> Mon, 10 Oct 2016 17:00:08 +1100 <![CDATA[RNS press release - Notice of AGM - Amendment ]]> Sat, 24 Sep 2016 02:24:18 +1000 <![CDATA[RNS press release - Notice of AGM ]]> Sat, 24 Sep 2016 00:28:39 +1000 <![CDATA[RNS press release - Final Results ]]> Fri, 16 Sep 2016 16:00:06 +1000 <![CDATA[RNS press release - Appointment of Non-Executive Director ]]> Mon, 22 Aug 2016 16:00:08 +1000 <![CDATA[RNS press release - Eurogentec manufacturing agreement ]]> Thu, 21 Jul 2016 16:00:08 +1000 <![CDATA[News - Scancell turns to Belgian group to replenish vaccine stocks ]]> Scancell Holdings Plc (LON:SCLP) will use Belgian group Eurogentec to manufacture a new batch of its SCIB1 ImmunoBody vaccine.

Scancell wants the drugs for a US clinical study of SCIB1 in combination with a checkpoint inhibitor that is expected to commence in 2017. 

It had to withdraw its stocks of SCIB1 in June after they went out of date having been held for seven years.

Once the US trial is completed, after around 9-12 months, the batch of SCIB1 will also be available to recommence dosing of patients in the long-term extension of a keenly watched Phase I/II clinical study in skin cancer. 

Eurogentec is a contract manufacturer that produces clinical trial and commercial biopharmaceutical material for all major markets including the US and Europe.

Richard Goodfellow, Scancell’s chief executive, said: "We are delighted to be working with Eurogentec, a world class manufacturer, to provide the new batch of SCIB1 material. 

“As can be seen from the latest data from our Phase 1/2 clinical trial, SCIB1 continues to deliver compelling survival data in patients with resected stage III/IV melanoma.

“This new supply will not only be used in our upcoming US checkpoint inhibitor combination trial, but also enable us to recommence treating patients in the long-term extension of the Phase 1/2 study. 

"Access to Eurogentec's expertise and proprietary manufacturing processes has the potential to substantially increase the yields of SCIB1 and fast-track the scale-up that will be required for future Phase III and commercial supply."

Thu, 21 Jul 2016 08:38:00 +1000
<![CDATA[RNS press release - Extension to Ichor Commercial Option ]]> Wed, 20 Jul 2016 16:00:07 +1000 <![CDATA[News - Scancell extends commercial licence with Ichor ]]> Cancer immunotherapy group Scancell Holdings Plc (LON:SCLP) has extended its commercial licence of Ichor Medical System’s electroporation delivery system, TriGrid for a further two years.

Scancell will continue to use Ichor’s system in conjunction with its flagship melanoma vaccine SCIB1.

TriGrid allows for the genetic manipulation of a cell by using pulses of electricity to momentarily open the pores of the cell membrane.

"Ichor's proprietary TriGrid electroporation delivery system remains central to our studies on SCIB1 and in particular, to our upcoming US clinical study of SCIB1 in combination with a checkpoint inhibitor, expected to commence in 2017,” said chief executive Richard Goodfellow.

In exchange, Scancell has granted a partial two-year waiver over the lock-up which prohibited the sale of Tranche 2 shares, as originally announced in July 2009 and extended in July 2014.

Subject to exercise of the Tranche two share options, Ichor will remain under an orderly market agreement requiring any sale during that two year period to be effected through Scancell's brokers.  

Wed, 20 Jul 2016 07:19:00 +1000
<![CDATA[News - Scancell’s cancer vaccine programme boosted by scientific review ]]> The scientific community have highlighted the potential of Scancell Holdings Plc’s (LON:SCLP) in-development cancer vaccines.

Scancell’s technology – which promises a completely new class of immuno-oncology therapeutics – has been peer reviewed in a scientific journal.

The report, in the Autophagy journal, discussed Scancell's pre-clinical supporting the innovation and potential of the company’s Moditope platform.

Scancell’s chief scientific officer Professor Lindy Durrant is lead author of the review, which discusses the concept that citrullinated peptides produced during autophagy offer attractive vaccine targets for cancer therapy.

Data described in the review - which had been separately published in another peer-reviewed journal – showed that a single immunization with Moditope resulted in long-term survival in up to 90% of mice.

“Moditope has a unique mechanism of action that overcomes the immune suppression induced by tumour cells, allowing T cells to seek out and kill tumours that would otherwise be hidden from the immune system,” Durrant said in a statement.

“We believe this platform has the potential to develop a new class of immuno-oncology therapeutics and look forward to progressing our first vaccine into the clinic as soon as possible."

It is expected that the first clinical trial coming from the platform will target patients with triple negative breast cancer, ovarian cancer and osteosarcoma.

Wed, 13 Jul 2016 07:25:00 +1000
<![CDATA[RNS press release - SCIB1 compelling survival data in melanoma ]]> Wed, 06 Jul 2016 16:00:06 +1000 <![CDATA[News - Scancell ever closer to tackling most deadly form of cancer ]]> With around 13,000 new cases of melanoma diagnosed annually and 2,000 deaths a year, skin cancer is the fifth most common cancer in the UK.

In fact, recent studies have found that malignant melanoma diagnoses hit 10,000 a year for over 55s alone, compared with just 3,100 cases two decades ago, an increase of 155%.

Dr Anton Alexandroff, a consultant dermatologist at Leicester Royal Infirmary, said the increase was likely due to “reckless” lifestyles and improper protection from the sun, which is the main cause of most skin cancers.

But Scancell Holdings Plc’s (LON:SCLP) latest data from trials of its ImmunoBody SCIB1 immunotherapy offer some promising results in a breakthrough treatment for this form of deadly cancer.

Priming the body to fight cancer

Scancell’s immunotherapy vaccine primes the patient’s immune system to recognise and kill specific cancer cells.

SCIB1 targets and stimulates existing cells that make up the body’s defence mechanisms, in particular the dendritic cells already present at the site of the cancer.

Dendritic cells are found in all tissues that are in contact with the external environment, such as the skin, lungs and intestines.

The main function of these cells is to process antigens - foreign or toxic material - and present them to the immune system. Once activated, they migrate to the lymph nodes where the antigen is destroyed by the body’s T cells.

In the study, 19 of the 20 patients with resected - or surgically removed - tumours when they entered the study remained alive. Of 16 patients who received doses 2-4mg of SCiB1, only five patients saw the tumour progress and one died.

Read more- Scancell Holdings says SCIB1 survival data is compelling

“There has only been one new case of disease progression since November 2013 in the resected patients receiving 4mg doses of SCIB1, which gives us hope that SCIB1 might offer curative potential in this currently untreated patient group," said Dr Richard Goodfellow, chief executive of Scancell.

Commenting on the data, Dr Keith Flaherty, director of the Termeer Center for Targeted Therapy at the Massachusetts General Hospital, said the results went “well beyond established norms for this group of melanoma patients”.

The new data should renew confidence in a group that has been making huge leaps in cancer immunotherapy research.

Analysts at Panmure Gordon said that this recent announcement continued to reflect “compelling survival data”. The broker said the recent study was persuasive and reiterated its Buy rating and target price of 68p.

Next round of clinical trials in the US

In July, the group renewed its licencing agreement with Ichor, the electroporation systems group, for a further two years. The technology allows for the genetic material of cells to be altered by using pulses of electricity to open the pores of the cell membrane. 

"This extension of two years gives us confidence to embark upon the next round of clinical trials that we’re planning in the United States,” said Goodfellow.

Russ Mould, investment director at AJ Bell, noted that shares in Scancell “put on a show of rude [health]” after it released a positive clinical trials update for SCIB1. Shares rose 10% following the announcement this to 16.5p.

Speaking to Proactive, Mould said shares were “way above their 12-month low of 12p, but well below the peak near 100p reached shortly after flotation back in 2010.”

But study results are not always enough to settle market sentiment. Mould said Scancell’s stock had come under pressure in the past year, amid wider concerns over valuations in the biotechnology sector on both sides of the Atlantic.

Over in the US, Hillary Clinton promised to intervene on drug pricing if she becomes President. The failure of some high-profile takeover deals in the US and the collapse of Valeant’s share price after an accounting scandal also contributed to concerns.


Wed, 06 Jul 2016 13:32:00 +1000
<![CDATA[News - Scancell Holdings says SCIB1 survival data is compelling ]]> Scancell Holdings Plc (LON:SCLP) hailed latest findings from the Phase 1/2 clinical trial of lead cancer drug SCIB1, which continues to show what it called "compelling" survival data.

The firm's first immunoBody candidate, named SCIB1, is being developed to treat melanoma - the most dangerous form of skin cancer.

Chief executive Dr Richard Goodfellow told investors on Wednesday that the drug continues to deliver compelling survival data in patients with resected Stage III/IV melanoma, where the diseased tissue has been cut away in surgery. 

"It is particularly interesting to note that there has only been one new case of disease progression since November 2013 in the resected patients receiving 4mg doses of SCIB1, which gives us hope that SCIB1 might offer curative potential in this currently untreated patient group," he added.

As at June  27, there were 19 of  20 patients with resected tumours when they entered the study that remain alive, the firm said, and of 16 patients who received 2-4mg doses of SCIB1, only one case of the disease progressing has been noted.

As reported on June 17, treatment for eight patients in the long-term continued dosing phase has been suspended due to the clinical trial supplies no longer being within the original specification

New SCIB1 material will be ready for use in around nine-12 months, the group added.

Meanwhile, plans for the US clinical study of SCIB1 in combination with a checkpoint inhibitor remain on track, while the final clinical study report will be issued later this year and give safety, immunology and clinical data from all patients up to October 29 last year - the date of the last patient's dose in the main study to support Scancell's US regulatory submission.

Shares gained over 13% to stand at 17p each.

Wed, 06 Jul 2016 07:31:00 +1000
<![CDATA[RNS press release - Second Price Monitoring Extn ]]> Thu, 30 Jun 2016 01:40:39 +1000 <![CDATA[RNS press release - Price Monitoring Extension ]]> Thu, 30 Jun 2016 01:35:19 +1000 <![CDATA[RNS press release - SCIB1 Drug Product Supply ]]> Fri, 17 Jun 2016 16:00:10 +1000 <![CDATA[News - Scancell working quickly to secure new supplies of drug ]]> Scancell Holdings Plc (LON:SCLP) said it is working as quickly as possible to secure new supplies of its flagship cancer drug SCIB1 after withdrawing the current batch.

The company said that quality control analysis revealed the “stored drug product is no longer within the original specification”.

“In discussion with the MHRA Clinical Trials Unit, and with patient safety of primary importance, the company has concluded that it is no longer suitable for further use, although no new side effects have emerged,” Scancell added.

The suspension affects eight of the 35 patients in the long-term extension arm of the phase 1/2 trial using SCIB1 to treat melanoma. Scancell stressed researchers have seen “no adverse events”.

SCIB1-001 was originally started in 2010 and the plan was simply to administer the drug to patients for six months.

But encouraging results and an excellent side-effect profile led to far longer dosing regimen than was intended and Scancell said some of the trial materials have now been stored for over seven years.  

It was planning with the help of a specialist manufacturer to make a fresh batch of SCIB1, which was to be used in combination with a checkpoint inhibitor to treat cancer patients.

However the new material will go first to those people on the extended trial.

Because the drug is thought to stimulate an immune response its anti-tumour effects should “persist” for the time it takes to source new supplies, which could be nine to 12 months.

"Patient safety has always been our primary responsibility,” said Scancell chief executive Dr Richard Goodfellow.

“Although we have seen no new adverse events it is unfortunate, but nevertheless appropriate, that we suspend dosing of SCIB1 at this time while we work as quickly as possible to secure new supplies of this promising potential treatment for melanoma.

“Starting further efficacy studies with SCIB1 is only possible due to the results we have seen so far in the long-running SCIB1-001 study and we would again like to convey our thanks to the patients in that trial  for their participation and support over the past six years."


Fri, 17 Jun 2016 07:27:00 +1000
<![CDATA[News - Scancell's immunotherapy platform to fight brain cancer ]]> Scancell Holdings PLC (LON:SCLP) technology is being used to develop a vaccine for the treatment of one of the most common and most aggressive forms of brain cancer.

Researchers at Nottingham Trent University and the University of Portsmouth have initiated a new preclinical study aimed at developing a vaccine for the treatment of glioblastoma multiforme, using Scancell’s Immunobody technology platform.

Glioblastoma multiforme accounts for just over half of all brain tumour diagnoses in the UK each year.

Current treatments are very limited and even with intensive chemotherapy; patients have an average survival time of just 14 months.

Using Scancell’s immunotherapy platform, scientists aim to develop a vaccine that stimulates the body’s immune system to target and kill the tumour cells.

“It is an aggressive disease and we believe the high avidity T cells generated by ImmunoBody will be needed to control its growth,” said chief scientific officer professor Lindy Durrant.

Thu, 02 Jun 2016 08:42:00 +1000
<![CDATA[News - Combined immunotherapies provide hope for skin cancer cure ]]> A new dual-therapy approach provides fresh hope for the treatment of one of the most common and deadliest of cancers.

Doctors at the Fred Hutchinson Cancer Research Centre in Seattle combined two forms of immunotherapy to trial a two-pronged attack on skin cancer.

The combination treatment was trialled on a 53-year-old patient with advanced melanoma who had shown little response to other treatments.

“Within weeks, the patient’s tumours began to shrink, and they eventually disappeared completely,” said the Research Centre in an official statement.

Writing in the Journal of Experimental Medicine, lead researcher Dr Cassian Yee revealed that over five years later, the patient remained completely cancer free.

The doctors used ipilimumab, a drug that activates the patient’s existing cancer fighting T cells by blocking the function of a protein called CTLA4 in conjunction with transplanted T cells from the patient’s immune system.

With around 13,000 new cases of melanoma diagnosed and 2,000 deaths each year, skin cancer is the fifth most common cancer in the UK.

“It’s only on a single patient but it highlights the importance of combining T cell stimulation with checkpoint inhibitors to control melanoma,” said Richard Goodfellow, chief executive of cancer therapy specialist Scancell (LON:SCLP).

Immunotherapies harness the body’s natural defences to fight cancer. Checkpoint inhibitors shut down the proteins in cancers which prevent the body from detecting and fighting tumour cells.

“That’s exactly what we are planning to do in the US with an 80 patient clinical trial led by Keith Flaherty in which we combine T cell stimulation (SCIB1) with a checkpoint inhibitor to increase response rates in melanoma,” added Goodfellow.

Wed, 01 Jun 2016 09:54:00 +1000
<![CDATA[RNS press release - Opens US Headquarters in San Diego ]]> Wed, 18 May 2016 16:00:08 +1000 <![CDATA[News - Scancell undergoes management reshuffle ]]> Scancell Holdings Plc (LON:SCLP) is set for a management reshuffle to support its ambitious growth plans.

Dr Richard Goodfellow, currently joint-CEO, will be appointed chief executive officer. Professor Lindy Durrant will step down from her role as joint-CEO and become chief science officer.

The company said the move will allow Durrant to focus fully on drug discovery.

Meanwhile, experienced biotech director Dr John Chiplin will assume the role of executive chairman - formerly non-executive chairman - and assist in raising Scancell’s corporate profile in the US. The group also announced that it had opened a new headquarters in San Diego.

Scancell also plans to establish a new base in Oxford for its UK corporate and development activities.

 “These changes align management with the strategic direction outlined at the time of our recent £6mln fundraising (April) and optimally leverage expertise with the needs of the company,” said Chiplin.

He highlighted that the group’s next generation cancer vaccine platforms were delivering “outstanding results.”


Wed, 18 May 2016 08:13:00 +1000
<![CDATA[RNS press release - Holding(s) in Company ]]> Tue, 12 Apr 2016 01:11:48 +1000